Coloplast has seen its share price fall a long way over the past few years, yet recent gains have nudged the stock higher again and put fresh focus on whether the current price lines up with the cash the business can generate. After such a mixed share price record, the key issue is whether the cash flow story supports where Coloplast trades today.
-
The stock is down 48.6% over 5 years. This puts the spotlight squarely on whether the cash flows behind the business still justify the market valuation.
-
Coloplast relies heavily on recurring demand in medical consumables, so expectations for steady cash conversion and limited capital needs can be a big swing factor in any cash flow based estimate of value.
-
What if you looked at Coloplast through its earnings instead? See why Coloplast's 38.5x P/E tells a different valuation story .
The issue now is whether Coloplast's current share price is adequately backed by the cash flows implied by a Discounted Cash Flow (DCF) intrinsic value estimate.
If you are weighing whether Coloplast's recent share price swings line up with its cash generation, it can help to compare that cash flow story with other businesses on the 191 high quality undervalued stocks .
Is Coloplast a Bargain on Cash Flow?
The Discounted Cash Flow model takes Coloplast's expected future cash generation and translates it into a present day estimate of worth. What stands out here is the scale and consistency of those cash flows. Latest twelve month free cash flow sits around DKK 6.2b, already a sizeable pool of cash for a business priced in the market at DKK472.20 per share.
Analyst projections in the DCF point to growing free cash flow over the coming years, with estimates in the model rising into the DKK 8b range and beyond. That pattern fits a mature healthcare supplier that tends to see recurring demand and does not need extreme capital spending to keep operations running. Because those projected DKK cash flows are substantial and extend well into the next decade, the DCF outcome sits substantially above where the stock changes hands today. This is why the model suggests the share price may not fully reflect Coloplast's cash generation potential right now. Find out what Coloplast could be worth using our Discounted Cash Flow (DCF) estimate .
The Coloplast Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Coloplast pick up where the DCF leaves off and spell out which paths for revenue, profitability and earnings would need to play out for the shares to look materially cheaper or more expensive than they do today on the screen. Where a single ratio or valuation model gives one headline number, these scenarios unpack the future that number relies on so you can watch how Coloplast's actual progress lines up over time on the Community page.
Coloplast's community is broadly constructive, but one group sees much more upside in the cash flows than the consensus target implies.
Bull case: 36% undervalued
"The cash flows cover the downside, while the re-rating towards the premium this business used to command is upside I am not paying for..."
Discover why this Narrative puts Coloplast at 36% undervalued .
Bear case: roughly fairly valued
"The current valuation and this narrative's fairly valued, bullish stance together imply that the share price already reflects meaningful long term success in U.S. scale up, sustained cash generation and disciplined capital allocation..."
Explore why this Narrative puts Coloplast at roughly fairly valued .
One more Coloplast check that belongs beside the price tag
Cash flows tell only part of Coloplast's story, because the people directing the business and the way their pay packets are structured can strongly influence how those numbers evolve over time. See who runs Coloplast and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include COLO-B.CO .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
